258 related articles for article (PubMed ID: 28470935)
21. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
[TBL] [Abstract][Full Text] [Related]
22. Verteporfin can Reverse the Paclitaxel Resistance Induced by YAP Over-Expression in HCT-8/T Cells without Photoactivation through Inhibiting YAP Expression.
Pan W; Wang Q; Zhang Y; Zhang N; Qin J; Li W; Wang J; Wu F; Cao L; Xu G
Cell Physiol Biochem; 2016; 39(2):481-90. PubMed ID: 27383277
[TBL] [Abstract][Full Text] [Related]
23. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
[TBL] [Abstract][Full Text] [Related]
24. MiR-361 targets Yes-associated protein (YAP) mRNA to suppress cell proliferation in lung cancer.
Zhang S; Liu Z; Wu L; Wang Y
Biochem Biophys Res Commun; 2017 Oct; 492(3):468-473. PubMed ID: 28837805
[TBL] [Abstract][Full Text] [Related]
25. YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes.
Mizuno T; Murakami H; Fujii M; Ishiguro F; Tanaka I; Kondo Y; Akatsuka S; Toyokuni S; Yokoi K; Osada H; Sekido Y
Oncogene; 2012 Dec; 31(49):5117-22. PubMed ID: 22286761
[TBL] [Abstract][Full Text] [Related]
26. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
27. YAP activation is an early event and a potential therapeutic target in liver cancer development.
Perra A; Kowalik MA; Ghiso E; Ledda-Columbano GM; Di Tommaso L; Angioni MM; Raschioni C; Testore E; Roncalli M; Giordano S; Columbano A
J Hepatol; 2014 Nov; 61(5):1088-96. PubMed ID: 25010260
[TBL] [Abstract][Full Text] [Related]
28. Identification of a derivative of the alkaloid emetine as an inhibitor of the YAP-TEAD interaction and its potential as an anticancer agent.
Sekine S; Takase S; Hayase R; Noritsugu K; Maemoto Y; Ichikawa Y; Ogawa K; Kondoh Y; Osada H; Yoshida M; Ito A
Biosci Biotechnol Biochem; 2023 Apr; 87(5):501-510. PubMed ID: 36809780
[TBL] [Abstract][Full Text] [Related]
29. Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma.
Saunders JT; Holmes B; Benavides-Serrato A; Kumar S; Nishimura RN; Gera J
J Neurooncol; 2021 Apr; 152(2):217-231. PubMed ID: 33511508
[TBL] [Abstract][Full Text] [Related]
30. Deregulation of the Hippo Pathway Promotes Tumor Cell Proliferation Through YAP Activity in Human Sporadic Vestibular Schwannoma.
Zhao F; Yang Z; Chen Y; Zhou Q; Zhang J; Liu J; Wang B; He Q; Zhang L; Yu Y; Liu P
World Neurosurg; 2018 Sep; 117():e269-e279. PubMed ID: 29902598
[TBL] [Abstract][Full Text] [Related]
31. Molecular Features of the YAP Inhibitor Verteporfin: Synthesis of Hexasubstituted Dipyrrins as Potential Inhibitors of YAP/TAZ, the Downstream Effectors of the Hippo Pathway.
Gibault F; Bailly F; Corvaisier M; Coevoet M; Huet G; Melnyk P; Cotelle P
ChemMedChem; 2017 Jun; 12(12):954-961. PubMed ID: 28334506
[TBL] [Abstract][Full Text] [Related]
32. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.
Slaninová V; Heron-Milhavet L; Robin M; Jeanson L; Aissanou A; Kantar D; Tosi D; Bréhélin L; Gongora C; Djiane A
BMC Cancer; 2024 May; 24(1):587. PubMed ID: 38741073
[TBL] [Abstract][Full Text] [Related]
33. The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC.
Jin D; Guo J; Wang D; Wu Y; Wang X; Gao Y; Shao C; Xu X; Tan S
EBioMedicine; 2018 Nov; 37():188-204. PubMed ID: 30389502
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo.
Li H; Huang Z; Gao M; Huang N; Luo Z; Shen H; Wang X; Wang T; Hu J; Feng W
J Exp Clin Cancer Res; 2016 Sep; 35(1):134. PubMed ID: 27599610
[TBL] [Abstract][Full Text] [Related]
35. Active epithelial Hippo signaling in idiopathic pulmonary fibrosis.
Gokey JJ; Sridharan A; Xu Y; Green J; Carraro G; Stripp BR; Perl AT; Whitsett JA
JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563341
[TBL] [Abstract][Full Text] [Related]
36. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway.
Mo JS; Meng Z; Kim YC; Park HW; Hansen CG; Kim S; Lim DS; Guan KL
Nat Cell Biol; 2015 Apr; 17(4):500-10. PubMed ID: 25751140
[TBL] [Abstract][Full Text] [Related]
37. A hairpin within YAP mRNA 3'UTR functions in regulation at post-transcription level.
Gao Y; Wang Y; Feng J; Feng G; Zheng M; Yang Z; Xiao Z; Lu Z; Ye L; Zhang X
Biochem Biophys Res Commun; 2015 Apr; 459(2):306-312. PubMed ID: 25727017
[TBL] [Abstract][Full Text] [Related]
38. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
[TBL] [Abstract][Full Text] [Related]
39. Fascin 1 promoted the growth and migration of non-small cell lung cancer cells by activating YAP/TEAD signaling.
Liang Z; Wang Y; Shen Z; Teng X; Li X; Li C; Wu W; Zhou Z; Wang Z
Tumour Biol; 2016 Aug; 37(8):10909-15. PubMed ID: 26886283
[TBL] [Abstract][Full Text] [Related]
40. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP.
Liu-Chittenden Y; Huang B; Shim JS; Chen Q; Lee SJ; Anders RA; Liu JO; Pan D
Genes Dev; 2012 Jun; 26(12):1300-5. PubMed ID: 22677547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
